We conducted a double-blind, placebo-controlled study of 40 patients (aged 19 to 60 years) with clinical definite relapsing remitting (RR) MS and brain MRI confirmed. Patients were randomly assigned to receive a loading dose of immunoglobulin IgG (0.4 g/kg/body weight per day for 5 consecutive days), followed by single booster doses (0.4 g/kg/body weight) or placebo once every 2 months for 2 years. The primary outcome measures were change in the yearly exacerbation rate (YER), proportion of exacerbation-free patients, and time until first exacerbation. Neurologic disability, exacerbation severity, and changes in brain MRI lesion score were the secondary outcome measures, all determined at baseline, 1 year, and on completion. Treated patients showed a reduction in YER from 1.85 to 0.75 after 1 year and 0.42 after 2 years versus 1.55 to 1.8 after 1 year and to 1.4 after 2 years in the placebo group (p = 0.0006, overall), reflecting a 38.6% reduction in relapse rate. Six patients in the IVIg group were exacerbation free throughout the 2-year period of the study, whereas none were exacerbation free in the placebo group. The median time to first exacerbation was 233 days in the IVIg group versus 82 days in the placebo group (p = 0.003). Neurologic disability as measured by the Expanded Disability Status Scale (EDSS score) decreased by 0.3 in the IVIg group and increased by 0.15 in the placebo group. Total lesion score evaluated by brain MRI did not show a significant difference between groups. Side effects were minor and occurred in only 19 of 630 (3.0%) infusions administered in both groups. Our results suggest that IVIg may be safe and effective in reducing the frequency of exacerbations in RR-MS.
Long-term prognosis and visual outcome of 54 patients with idiopathic intracranial hypertension (IIH) was studied. Mean observation period was 6.2 years; 33 patients had two or more recurrences. Visual acuity was preserved in all patients without recurrence and in 86% of patients with recurrences. Recurrences did not occur while patients were maintained on acetazolamide. No statistical difference was found between IIH patients who had only one event, compared to the recurrent group.
A consecutive series of 30 cases of extracranial medulloblastoma metastases in adults is analysed. The majority of the patients were males with a 3:1 male/female ratio. Bone was the most frequent site of metastases in adults (77%) and children (78%), followed by lymph nodes (33%) in both children and adults. Lung metastases were more common in adults (17%), but liver metastases occurred more frequently in children (15%). Case report A 33 year old male presented with severe headache and vomiting. On physical examination, he showed bilateral papilloedema and severe ataxia and incoordination. Brain computerised tomography (CT) demonstrated a large mass, 5 cm in diameter, in the vermis and right cerebellar lobe. Suboccipital craniotomy was performed and a large, soft greyish cerebellar tumour, extending into the roof of the fourth ventricle, was totally excised. The tumour was found to be a medulloblastoma. A post-operative CT scan did not reveal any residual tumour. The patient subsequently received radiation therapy: whole brain-3600 RAD, posterior fossa-5200 RAD, total spine-3000 RAD. On discharge, the patient had no neurological deficit and remained symptomless.Twenty one months after corrective surgery, however, low back pain and micturition difficulties appeared, and within two weeks, urinary retention developed, with paraparesis and loss of sphincter control. Myelography showed a partial block at T7 and a complete block at T3, with multiple intradural lesions along the dural sac. CT scan revealed a hypodense area in the roof of the fourth ventricle, containing a discrete area with some contrast enhancement. Bone radio-isotope scan showed increased absorption in thoracic vertebrae TI-TIo, in most ribs, and in the sternum, pelvis and both femurs. Liver radioisotope scan revealed several foci of increased absorption, and a chest radiograph demonstrated multiple pulmonary metastases. Bone marrow biopsy revealed an infiltration of numerous tumour cells diagnosed as medulloblastoma, with large areas of necrosis and fibrosis. The patient received a course of radiation therapy and a course of C-MOPP. However, his condition gradually deteriorated and he died two months later.To the best of our knowledge, although questions of incidence of extracranial metastases of medulloblastoma, location, mode of spread and survival have been discussed in previous reviews, none of them have separately discussed the problem of extracranial metastases of medulloblastoma in adults. Results and commentsIn 1930 Bailley5 demonstrated that medulloblastomas tended to seed along cerebrospinal fluid (CSF) pathways, and in the same year Wohlvill6 was the first to draw attention to the occurrence of systemic metastasis of a medulloblastoma. Since then, metastases within the central nervous system 80 on 7 May 2018 by guest. Protected by copyright.
Pseudotumor cerebri in males is relatively rare. The clinical features are identical to those found in females. The fact that the majority of the male patients had a normal body weight may indicate that increased body weight does not play a major role in causing PTC in men, whereas it is an established major risk factor in women.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.